Short Interest in ABVC BioPharma, Inc. (NASDAQ:ABVC) Decreases By 59.6%

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the recipient of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 533,000 shares, a decrease of 59.6% from the March 31st total of 1,320,000 shares. Based on an average trading volume of 946,600 shares, the short-interest ratio is presently 0.6 days. Approximately 6.1% of the company’s shares are sold short.

ABVC BioPharma Price Performance

ABVC stock traded up $0.11 during trading on Thursday, reaching $1.59. The company had a trading volume of 5,330,633 shares, compared to its average volume of 2,109,203. ABVC BioPharma has a 52 week low of $0.67 and a 52 week high of $9.60. The company has a market cap of $16.79 million, a P/E ratio of -0.68 and a beta of 0.75. The business has a 50 day moving average of $1.20 and a 200 day moving average of $1.25.

ABVC BioPharma (NASDAQ:ABVC) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.35) earnings per share (EPS) for the quarter. ABVC BioPharma had a negative return on equity of 226.65% and a negative net margin of 6,919.08%.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer.